Product Name :
Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody
EN
VEGF, VEGF-A, vascular endothelial growth factor A
Source:
The anti-human vascular endothelial growth factor A (VEGF-A) monoclonal antibody brolucizumab biosimilar was produced in mammalian cells.
Molecular Weight:
Activity :
Purity:
>95% by SDS-PAGE under reducing conditions and HPLC.
Endotoxin :
<1 EU/mg of the protein by the LAL method.
Formulation:
Reconstitution :
Shipping:
The research grade brolucizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
/strong>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Form of Antibody :
0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Clone:
Isotype:
Human IgG1 kappa.
Background:
Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. Syd Labs also provides the following anti-VEGF antibody biosimilar proteins: Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Additional Information:
| Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody Recombinant Humanized IgG1 Monoclonal Antibody. |Isotype: Human IgG1 kap|The anti-human vascular endothel growth factor A (VEGF-A) monoclonal antibody brolucizumab biosimilar was produced in mammal cells. |Specificity/Sensitivity: The in vivo grade brolucizumab biosimilar specifically binds to the human vascular endothel growth factor A (VEGF-A). |Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |Endotoxin: |Purity: >95% by SDS-|The research grade brolucizumab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothel growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothel cells, vascularization of the tissue, and permeability of the vasculature. Syd Labs also provides the following anti-VEGF antibody biosimilar proteins: Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
PDGFR alpha Antibody
p38 alpha/MAPK14 Antibody
CD45 Antibody (YA800): CD45 Antibody (YA800) is a non-conjugated and Mouse origined monoclonal antibody about 147 kDa, targeting to CD45. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.
